CRSP CRISPR Therapeutics AG

53.88
-0.87  -2%
Previous Close 54.75
Open 52.5
Price To Book 5.12
Market Cap 3,027,618,269
Shares 56,194,066
Volume 479,668
Short Ratio
Av. Daily Volume 1,310,747
Stock charts supplied by TradingView

NewsSee all news

  1. CRISPR Therapeutics to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top Conference

    ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases,

  2. Repare Therapeutics Appoints Steve Forte as CFO and Samarth Kulkarni to Its Board of Directors

    Repare Therapeutics, a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in genetically defined patient populations, announced today

  3. CRISPR Therapeutics to Present at Upcoming Investor Conferences

    ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 27, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases,

  4. CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares

    ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 20, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases,

  5. CRISPR Therapeutics Announces Proposed Public Offering of Common Shares

    ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 19, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 initial data noted patient is free of vaso-occlusive crises - November 19, 2019.
CTX001
Sickle cell disease
Phase 1/2 initial data noted patient is transfusion independent - November 19, 2019.
CTX001
Beta-thalassemia
Phase 1/2 enrolment has commenced - July 29, 2019.
CTX110
CD19+ malignancies

Latest News

  1. CRISPR Therapeutics to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top Conference

    ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases,

  2. Repare Therapeutics Appoints Steve Forte as CFO and Samarth Kulkarni to Its Board of Directors

    Repare Therapeutics, a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in genetically defined patient populations, announced today

  3. CRISPR Therapeutics to Present at Upcoming Investor Conferences

    ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 27, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases,

  4. CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares

    ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 20, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases,

  5. CRISPR Therapeutics Announces Proposed Public Offering of Common Shares

    ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 19, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases,

  6. CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies

    -Two patients treated with CTX001 successfully engrafted and demonstrated an initial safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant- -Beta

  7. CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies' Respective Cell Therapy Programs in Oncology

    - CRISPR Therapeutics to receive non-exclusive access to certain KSQ IP for its allogeneic CAR-T programs - - KSQ Therapeutics to receive non-exclusive access to certain CRISPR IP for its autologous cell therapies,

  8. CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies' Respective Cell Therapy Programs in Oncology

    - CRISPR Therapeutics to receive non-exclusive access to certain KSQ IP for its allogeneic CAR-T programs - - KSQ Therapeutics to receive non-exclusive access to certain CRISPR IP for its autologous cell therapies,

  9. CRISPR Therapeutics to Present at Upcoming Investor Conferences

    ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases,

  10. CRISPR Therapeutics and ViaCyte Present Positive In Vitro Data Towards a Potential Immune-Evasive Cell Replacement Therapy for Diabetes at EASD 2019

    -New data demonstrate successful differentiation of CRISPR-edited human pluripotent stem cells to pancreatic precursor cells- ZUG, Switzerland, CAMBRIDGE, Mass., and SAN DIEGO, Sept. 17, 2019 (GLOBE NEWSWIRE) --